Unpacking Key Data in Chronic Myeloid Leukemia After ASH 2024 - Episode 1
Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
